FDA BE guidance for ANDAs (PK endpoints)
Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA
Current edition
May 2026
Current edition
May 2026
About this standard
Gives recommendations to generic drug applicants on bioequivalence studies that use pharmacokinetic measures, including study design, subjects, fasting and fed conditions and analysis.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
United States
- Bioequivalence studies with pharmacokinetic endpoints for generic drugsBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.